NCT03242239View on ClinicalTrials.gov

A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 9, 2016

Primary Completion Date

August 4, 2016

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
BIOLOGICAL

ALT02

BIOLOGICAL

EU-licensed Herceptin

BIOLOGICAL

US-licensed Herceptin

Sponsors

Lead Sponsor

Alteogen, Inc.
All Listed Sponsors
collaborator

Cristália Produtos Químicos Farmacêuticos Ltda.

INDUSTRY

lead

Alteogen, Inc.

INDUSTRY